Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Generic Ribavirin Launch Expected In “Weeks”; ANDA Is “Approvable”

Executive Summary

Par is forecasting a launch of generic Rebetol (ribavirin) in the first quarter following a Feb. 22 FDA "approvable" letter

You may also be interested in...



Par Stands By “Authorized” Generics; “More Creative” Deals Coming

Drug patent dispute settlements are likely to become more "creative" in the future, Par CEO Scott Tarriff says

Par Stands By “Authorized” Generics; “More Creative” Deals Coming

Drug patent dispute settlements are likely to become more "creative" in the future, Par CEO Scott Tarriff says

“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says

At least eight first-time ANDA approvals over the next two years could require a determination of whether 180-day "shared exclusivity" should be awarded, FDA says in a court filing

Related Content

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel